|
|
|
| |
|
|
<![CDATA[<code id='1DDBECED9C'></code><style id='1DDBECED9C'></style>]]> | <![CDATA[<acronym id='1DDBECED9C'></acronym>]]><![CDATA[<center id='1DDBECED9C'><center id='1DDBECED9C'><tfoot id='1DDBECED9C'></tfoot></center><abbr id='1DDBECED9C'><dir id='1DDBECED9C'><tfoot id='1DDBECED9C'></tfoot><noframes id='1DDBECED9C'>]]>
| <![CDATA[<optgroup id='1DDBECED9C'><strike id='1DDBECED9C'><sup id='1DDBECED9C'></sup></strike><code id='1DDBECED9C'></code></optgroup>]]>
| |
|
|
| <![CDATA[<b id='1DDBECED9C'><label id='1DDBECED9C'><select id='1DDBECED9C'><dt id='1DDBECED9C'><span id='1DDBECED9C'></span></dt></select></label></b><u id='1DDBECED9C'></u>]]> | |
<![CDATA[<i id='1DDBECED9C'><strike id='1DDBECED9C'><tt id='1DDBECED9C'><pre id='1DDBECED9C'></pre></tt></strike></i>]]>|
内容简介：
大参林、中国生物、自2023年下半年国家卫健委会同九部门启动全国医药领域腐败问题集中整治工作以来，过去一年，华厦眼科、沃华医药、环球医疗等国内知名药企均有相关高管牵涉进医药领域腐败案件。已有30余位药
